by FiveSenses | Apr 23, 2024 | News Release
Vancouver, BC, Canada, April 23rd, 2024 – Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC), a Canadian biopharmaceutical company developing novel immune-oncology therapeutics and drug delivery technologies, is pleased to... 
by FiveSenses | Apr 17, 2024 | News Release
Vancouver, BC, Canada, April 17th, 2024 – Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC), a Canadian biopharmaceutical company developing novel immune-oncology therapeutics and drug delivery technologies, is... 
by FiveSenses | Apr 5, 2024 | News Release
Vancouver, BC, Canada, April 5th, 2024 – Defence Therapeutics Inc. (“Defence” or the “Company”), one of the leading Canadian biotechnology companies working in the field of immune-oncology, announces an amendment to the terms of 1,497,780 Class A Common share...
Recent Comments